Overview
Severe malaria (also called complicated malaria) is a life‑threatening manifestation of infection with Plasmodium parasites, most commonly P. falciparum. While most malaria cases are uncomplicated and respond to oral therapy, severe malaria involves organ dysfunction, metabolic derangements, or profound anemia that requires urgent intravenous treatment and intensive monitoring.
It affects primarily children under five years of age and pregnant women in endemic regions, but travelers returning from endemic areas can also develop severe disease if diagnosis is delayed.
Global burden (2022):
- ≈ 247 million malaria cases worldwide (World Health Organization, WHO).
- ≈ 619,000 deaths, > 95% of which occur in sub‑Saharan Africa.
- Severe malaria accounts for roughly 1–2% of all malaria infections but causes > 80% of malaria‑related deaths.
Prompt recognition and treatment dramatically reduces mortality—from > 20% in untreated patients to < 5% in settings with rapid intravenous therapy and intensive care.
Symptoms
Severe malaria is diagnosed when a patient with confirmed malaria develops any of the following life‑threatening complications (World Health Organization criteria):
Neurological
- Cerebral malaria: Unarousable coma (Glasgow Coma Scale ≤ 11) lasting ≥ 1 hour after correcting hypoglycemia.
- Seizures (often focal or generalized).
- Confusion, agitation, or delirium.
Hematologic
- Severe anemia: Hemoglobin < 5 g/dL (or a drop > 2 g/dL in 48 h).
- Hemoglobinuria (“dark urine”) from massive hemolysis.
Respiratory
- Acute respiratory distress syndrome (ARDS) – rapid breathing, low oxygen saturation.
- Pulmonary edema.
Cardiovascular
- Hypotension or shock unresponsive to fluid resuscitation.
- Acute myocardial dysfunction (rare).
Renal
- Acute kidney injury (creatinine > 2 mg/dL or oliguria < 0.5 mL/kg/h).
Metabolic
- Severe hypoglycemia (blood glucose < 2.2 mmol/L or < 40 mg/dL), especially in children and pregnant women.
- Metabolic acidosis (base excess < ‑8 mmol/L, lactate > 5 mmol/L).
- Hyperbilirubinemia (jaundice) and elevated liver enzymes.
Other signs
- Persistent vomiting, inability to retain oral medication.
- High fever (> 40 °C/104 °F) with chills.
- Extreme lethargy or inability to drink.
Causes and Risk Factors
Cause
Malaria is transmitted through the bite of an infected female Anopheles mosquito. The parasite lifecycle includes:
- Sporozoites enter the bloodstream and travel to the liver.
- They mature into merozoites that burst into the bloodstream, infecting red blood cells (RBCs).
- In severe malaria, a high burden of parasitized RBCs leads to sequestration of infected cells in the microvasculature, causing organ dysfunction.
P. falciparum is responsible for > 95% of severe cases because its proteins (e.g., PfEMP1) cause strong cyto‑adherence to endothelial cells.
Risk Factors
- Geographic exposure: Living in or traveling to high‑transmission areas (sub‑Saharan Africa, parts of Southeast Asia, the Amazon basin).
- Age: Children < 5 years have less immunity and smaller blood volume.
- Pregnancy: Placental sequestration increases parasite load.
- Immunocompromised states: HIV, malnutrition, splenectomy.
- Delayed diagnosis or treatment: Lack of access to rapid diagnostic tests (RDTs) or antimalarials.
- Resistance: Infections with drug‑resistant P. falciparum strains (e.g., artemisinin resistance in the Greater Mekong Subregion).
Diagnosis
Accurate, rapid diagnosis is essential because severe malaria can progress in hours.
Clinical assessment
- Detailed travel or exposure history.
- Physical exam focusing on neurologic status, respiratory effort, jaundice, and signs of shock.
Laboratory tests
- Microscopy (thick and thin blood smears): Gold standard; quantifies parasite density (parasites/µL). A parasite count > 10 % of RBCs strongly predicts severe disease.
- Rapid Diagnostic Tests (RDTs): Detect HRP2 antigen; useful when microscopy unavailable, but do not quantify parasitemia.
- Complete blood count (CBC): Evaluates anemia, thrombocytopenia.
- Blood glucose: Immediate finger‑stick; treat hypoglycemia promptly.
- Renal panel & electrolytes: Detect acute kidney injury, metabolic acidosis.
- Liver function tests (LFTs): Assess bilirubin, transaminases.
- Arterial blood gas (ABG): Evaluates oxygenation and acid‑base status.
- Lactate level: Elevated > 5 mmol/L is a marker of severe disease.
Imaging (when indicated)
- Chest X‑ray for pulmonary edema/ARDS.
- Head CT or MRI if focal neurologic deficits raise concern for intracranial hemorrhage (rare).
Treatment Options
General principles
- Initiate intravenous (IV) antimalarial therapy within 1 hour of diagnosis.
- Provide supportive care in an intensive‑care or high‑dependency setting.
- Treat complications (e.g., seizures, hypoglycemia, renal failure) concurrently.
First‑line antimalarial agents
| Drug | Regimen | Key notes |
|---|---|---|
| Artesunate (IV) | 2.4 mg/kg at 0 h, 12 h, then daily until able to take oral therapy | WHO‑recommended; superior to quinine (mortality reduction ~ 35%). |
| Quinine (IV) | 10 mg/kg loading dose, then 10 mg/kg q8h | Used where artesunate unavailable; monitor for cinchonism, hypoglycemia. |
| Artemisinin‑based combination therapy (ACT) – oral | Switch once patient can tolerate oral intake (usually after 24 h of IV therapy) | Examples: artemether‑lumefantrine, artesunate‑amodiaquine. |
Adjunctive therapies
- Parenteral quinine or artesunate plus clindamycin: For areas with documented artemisinin resistance.
- Antipyretics (acetaminophen): Control high fever; avoid NSAIDs in severe renal impairment.
- Anticonvulsants (e.g., diazepam, levetiracetam): For seizures associated with cerebral malaria.
- Glucose infusion: Prevent/treat hypoglycemia; monitor serum glucose frequently.
- Fluid management: Isotonic crystalloids; avoid overload in ARDS or renal failure.
- Renal replacement therapy: For severe AKI unresponsive to fluids.
- Blood transfusion: If hemoglobin < 5 g/dL or symptomatic anemia.
Lifestyle & supportive measures
- Bed rest until afebrile for at least 48 h.
- Hydration with oral rehydration solutions when tolerated.
- Nutrition: high‑protein, high‑calorie diet to aid recovery.
Living with Severe Malaria
Hospital phase (first 1–2 weeks)
- Monitor vitals every hour initially; then every 4–6 h as stable.
- Daily labs: CBC, renal panel, LFTs, glucose.
- Educate caregivers on signs of relapse (fever, chills, headache).
Post‑discharge care
- Complete the full ACT course (usually 3 days) even if feeling well.
- Schedule follow‑up at 7 days and 28 days to repeat smear or rapid test; ensure parasite clearance.
- Neurocognitive assessment for children with cerebral malaria – many recover, but some develop developmental delays.
- Vaccination updates (e.g., pneumococcal, influenza) to reduce secondary infections.
- Psychosocial support: severe malaria can be traumatic; consider counseling for anxiety or post‑traumatic stress.
Prevention
Personal protective measures
- Insecticide‑treated bed nets (ITNs): Reduce night‑time bites; efficacy > 50 % in reducing severe malaria.
- Indoor residual spraying (IRS): In high‑transmission settings.
- Protective clothing: Long sleeves, pants, and hats during dusk‑dawn.
- Repellents: DEET 20–30 % or picaridin applied to skin and clothing.
Chemoprophylaxis for travelers
| Region | Recommended drug(s) | Dosage & timing |
|---|---|---|
| Sub‑Saharan Africa | Atovaquone‑proguanil (Malarone) | One tablet daily; start 1 day before travel, continue 7 days after return. |
| Same region | Doxycycline | 100 mg daily; start 1–2 days before travel, continue 4 weeks after return. |
| Southeast Asia (areas with chloroquine‑resistant falciparum) | Mefloquine (if no contraindications) | 250 mg weekly; start 2–3 weeks before travel, continue 4 weeks after return. |
Community‑level interventions
- Mass drug administration (MDA) in outbreak zones.
- Larval source management (drainage, larvicides).
- Vaccination: RTS,S/AS01 (Mosquirix) – WHO recommends for children in high‑transmission African settings; reduces severe malaria by ≈ 30 %.
Complications
If untreated or inadequately treated, severe malaria can progress to irreversible organ damage.
- Cerebral sequelae: Persistent neurological deficits, epilepsy, cognitive impairment.
- Acute kidney injury: May require dialysis; risk of chronic kidney disease.
- Pulmonary complications: ARDS with high mortality (≈ 30 % in adults).
- Severe anemia: Cardiac decompensation, need for repeated transfusions.
- Congenital malaria: Infected newborns may present with severe disease.
- Hemolysis‑related jaundice: Can lead to hepatic dysfunction.
- Secondary bacterial infection: Due to immune suppression.
When to Seek Emergency Care
Immediate medical attention is required if any of the following occur:
- Unresponsive or difficult to awaken (possible cerebral malaria).
- Severe or persistent vomiting preventing oral medication.
- Rapid breathing, chest pain, or difficulty speaking.
- Cold, clammy skin, or a rapid weak pulse (signs of shock).
- Dark urine, jaundice, or sudden pallor.
- Confusion, seizures, or new focal neurologic deficits.
- Blood glucose < 2.2 mmol/L (40 mg/dL) or inability to test.
- Any fever in a traveler returning from a malaria‑endemic area within the past 12 months.
Call emergency services or go to the nearest hospital with an intensive‑care unit.
References
- World Health Organization. World Malaria Report 2022. WHO; 2022.
- Mayo Clinic. Severe malaria: Symptoms and causes. https://www.mayoclinic.org/diseases-conditions/malaria/in-depth/severe-malaria/art-20047326
- Cleveland Clinic. Malaria – Diagnosis and treatment. https://my.clevelandclinic.org/health/diseases/13059-malaria
- CDC. Malaria Treatment Guidelines, 2023. https://www.cdc.gov/malaria/diagnosis_treatment.html
- NIH. Artesunate for severe malaria. https://clinicaltrials.gov/ct2/show/NCT03231144
- Shretta R, et al. Cerebral malaria in children – long‑term outcomes. J Infect Dis. 2021;224(9):1523‑1530.